BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang S, Bester L, Burnes J, Clouston J, Hugh T, Little A, Padbury R, Price D. Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancer: 90Y microsphere treatment for liver cancer. Journal of Medical Imaging and Radiation Oncology 2010;54:178-87. [DOI: 10.1111/j.1754-9485.2010.02167.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Tan AE, Kao YH, Xie W. Excessive Hepatic Arterial-portal Venous Shunting May Predict Failure of Microparticle Localization in Hepatocellular Carcinomas. World J Nucl Med 2013;12:48-50. [PMID: 23961258 DOI: 10.4103/1450-1147.113966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
2 Krijger GC, Ponsard B, Harfensteller M, Wolterbeek HT, Nijsen JW. The necessity of nuclear reactors for targeted radionuclide therapies. Trends Biotechnol 2013;31:390-6. [PMID: 23731577 DOI: 10.1016/j.tibtech.2013.04.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
3 Kucuk ON, Soydal C, Araz M, Ozkan E, Aras G. Evaluation of the Response to Selective Internal Radiation Therapy in Patients With Hepatocellular Cancer According to Pretreatment 99mTc-MAA Uptake. Clinical Nuclear Medicine 2013;38:252-5. [DOI: 10.1097/rlu.0b013e31828162e8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Bester L, Meteling B, Pocock N, Saxena A, Chua TC, Morris DL. Radioembolisation with Yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases. J Med Imaging Radiat Oncol. 2013;57:72-80. [PMID: 23374558 DOI: 10.1111/j.1754-9485.2012.02459.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
5 Kim YH, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology. 2013;84 Suppl 1:34-39. [PMID: 23428856 DOI: 10.1159/000345887] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
6 Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med. 2011;25:455-461. [PMID: 21643807 DOI: 10.1007/s12149-011-0499-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
7 Clements W. The evolution of interventional radiology literature in Australia and New Zealand. J Med Imaging Radiat Oncol 2020;64:366-7. [PMID: 32216039 DOI: 10.1111/1754-9485.13026] [Reference Citation Analysis]
8 Kao YH, Steinberg JD, Tay YS, Lim GK, Yan J, Townsend DW, Takano A, Burgmans MC, Irani FG, Teo TK, Yeow TN, Gogna A, Lo RH, Tay KH, Tan BS, Chow PKh, Satchithanantham S, Tan AE, Ng DC, Goh AS. Post-radioembolization yttrium-90 PET/CT - part 1: diagnostic reporting. EJNMMI Res 2013;3:56. [PMID: 23883566 DOI: 10.1186/2191-219X-3-56] [Cited by in Crossref: 56] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
9 Webster LA, Villalobos A, Majdalany BS, Bercu ZL, Gandhi RT, Kokabi N. Standard Radiation Dosimetry Models: What Interventional Radiologists Need to Know. Semin Intervent Radiol 2021;38:405-11. [PMID: 34629706 DOI: 10.1055/s-0041-1732323] [Reference Citation Analysis]
10 Kao YH, Tan EH, Teo TKB, Ng CE, Goh SW. Imaging discordance between hepatic angiography versus Tc-99m-MAA SPECT/CT: a case series, technical discussion and clinical implications. Ann Nucl Med 2011;25:669-76. [DOI: 10.1007/s12149-011-0516-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
11 Shukla PA, Ahuja J, Kurli V, Patel RI, Kozuch PS. Gastric Perforation Following Prophylactic Embolization of Right Gastric and Gastroduodenal Arteries Prior to Selective Internal Radiation Therapy. Cardiovasc Intervent Radiol. 2015; Jun 13. [Epub ahead of print]. [PMID: 26071106 DOI: 10.1007/s00270-015-1139-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Bester L, Meteling B, Boshell D, Saxena A, Morris DL. Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer. Hepat Oncol 2014;1:215-28. [PMID: 30190956 DOI: 10.2217/hep.13.21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
13 Villalobos A, Soliman MM, Majdalany BS, Schuster DM, Galt J, Bercu ZL, Kokabi N. Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know. Semin Intervent Radiol 2020;37:543-54. [PMID: 33328711 DOI: 10.1055/s-0040-1720954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sperling J, Justinger C, Schuld J, Ziemann C, Seidel R, Kollmar O. Intrahepatic cholangiocarcinoma in a transplant liver--selective internal radiation therapy followed by right hemihepatectomy: report of a case. World J Surg Oncol 2014;12:198. [PMID: 24980217 DOI: 10.1186/1477-7819-12-198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Song MJ, Bae SH. Newer treatments for advanced hepatocellular carcinoma. Korean J Intern Med. 2014;29:149-155. [PMID: 24648795 DOI: 10.3904/kjim.2014.29.2.149] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
16 Krug S, Bartsch DK, Schober M, Librizzi D, Pfestroff A, Burbelko M, Moll R, Michl P, Gress TM. Successful selective internal radiotherapy (SIRT) in a patient with a malignant solid pseudopapillary pancreatic neoplasm (SPN). Pancreatology 2012;12:423-7. [PMID: 23127531 DOI: 10.1016/j.pan.2012.07.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol 2013;36:158-65. [PMID: 22526099 DOI: 10.1007/s00270-012-0373-5] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 5.4] [Reference Citation Analysis]
18 Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, El-haddad G, Kis B, Sweeney J, Meredith KL, Almhanna K, Strosberg J, Shibata D, Fulp WJ, Shridhar R. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clinical Colorectal Cancer 2015;14:146-53. [DOI: 10.1016/j.clcc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
19 Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84:311-318. [PMID: 23615394 DOI: 10.1159/000348325] [Cited by in Crossref: 91] [Cited by in F6Publishing: 98] [Article Influence: 10.1] [Reference Citation Analysis]
20 Bester L, Meteling B, Boshell D, Chua TC, Morris DL. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: A review of the literature: Embolisation therapies in liver cancer. Journal of Medical Imaging and Radiation Oncology 2014;58:341-52. [DOI: 10.1111/1754-9485.12163] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
21 Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, Tay KH, Tan BS, Hoe Chow PK, Eng Ng DC, Whatt Goh AS. Image-Guided Personalized Predictive Dosimetry by Artery-Specific SPECT/CT Partition Modeling for Safe and Effective 90 Y Radioembolization. J Nucl Med 2012;53:559-66. [DOI: 10.2967/jnumed.111.097469] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 10.9] [Reference Citation Analysis]
22 Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer 2013;132:2349-58. [PMID: 23047645 DOI: 10.1002/ijc.27894] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
23 Haidu M, Dobrozemsky G, Schullian P, Widmann G, Klaus A, Weiss H, Margreiter R, Bale R. Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol. 2012;35:1074-1082. [PMID: 22006031 DOI: 10.1007/s00270-011-0288-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
24 Revel-Mouroz P, Otal P, Jaffro M, Petermann A, Meyrignac O, Rabinel P, Mokrane FZ. Other non-surgical treatments for liver cancer. Rep Pract Oncol Radiother 2017;22:181-92. [PMID: 28490991 DOI: 10.1016/j.rpor.2017.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]